1
|
Intrinsic thermodynamics of inhibitor binding to human carbonic anhydrase IX. Biochim Biophys Acta Gen Subj 2016; 1860:708-18. [DOI: 10.1016/j.bbagen.2016.01.007] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 12/30/2015] [Accepted: 01/12/2016] [Indexed: 12/26/2022]
|
2
|
Defert O, Boland S. Kinase profiling in early stage drug discovery: sorting things out. DRUG DISCOVERY TODAY. TECHNOLOGIES 2015; 18:52-61. [PMID: 26723893 DOI: 10.1016/j.ddtec.2015.10.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Accepted: 10/07/2015] [Indexed: 01/07/2023]
Abstract
Protein kinases represent one of the largest superfamilies of drugable targets and a major research area for both the pharmaceutical industry and academic groups. This has resulted in the emergence of numerous screening technologies and services dedicated to kinase profiling. In spite of this plentiful offering, the field is not without its own pitfalls, as the profusion of reported conditions and data can ultimately complicate interpretation of project results. Here, we discuss how kinase profiling was used in our early stage drug discovery efforts, from the perspective of a smaller biotech relying largely on assay outsourcing.
Collapse
Affiliation(s)
- Olivier Defert
- Amakem Therapeutics N.V. Agoralaan Abis, 3590 Diepenbeek, Belgium.
| | - Sandro Boland
- Amakem Therapeutics N.V. Agoralaan Abis, 3590 Diepenbeek, Belgium
| |
Collapse
|
3
|
Ciglia E, Vergin J, Reimann S, Smits SHJ, Schmitt L, Groth G, Gohlke H. Resolving hot spots in the C-terminal dimerization domain that determine the stability of the molecular chaperone Hsp90. PLoS One 2014; 9:e96031. [PMID: 24760083 PMCID: PMC3997499 DOI: 10.1371/journal.pone.0096031] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2013] [Accepted: 04/02/2014] [Indexed: 12/24/2022] Open
Abstract
Human heat shock protein of 90 kDa (hHsp90) is a homodimer that has an essential role in facilitating malignant transformation at the molecular level. Inhibiting hHsp90 function is a validated approach for treating different types of tumors. Inhibiting the dimerization of hHsp90 via its C-terminal domain (CTD) should provide a novel way to therapeutically interfere with hHsp90 function. Here, we predicted hot spot residues that cluster in the CTD dimerization interface by a structural decomposition of the effective energy of binding computed by the MM-GBSA approach and confirmed these predictions using in silico alanine scanning with DrugScore(PPI). Mutation of these residues to alanine caused a significant decrease in the melting temperature according to differential scanning fluorimetry experiments, indicating a reduced stability of the mutant hHsp90 complexes. Size exclusion chromatography and multi-angle light scattering studies demonstrate that the reduced stability of the mutant hHsp90 correlates with a lower complex stoichiometry due to the disruption of the dimerization interface. These results suggest that the identified hot spot residues can be used as a pharmacophoric template for identifying and designing small-molecule inhibitors of hHsp90 dimerization.
Collapse
Affiliation(s)
- Emanuele Ciglia
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University, Düsseldorf, Germany
| | - Janina Vergin
- Institute for Biochemical Plant Physiology, Heinrich-Heine-University, Düsseldorf, Germany
| | - Sven Reimann
- Institute of Biochemistry, Heinrich-Heine-University, Düsseldorf, Germany
| | - Sander H. J. Smits
- Institute of Biochemistry, Heinrich-Heine-University, Düsseldorf, Germany
| | - Lutz Schmitt
- Institute of Biochemistry, Heinrich-Heine-University, Düsseldorf, Germany
| | - Georg Groth
- Institute for Biochemical Plant Physiology, Heinrich-Heine-University, Düsseldorf, Germany
| | - Holger Gohlke
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University, Düsseldorf, Germany
| |
Collapse
|
4
|
Huang X, Shipps GW, Cheng CC, Spacciapoli P, Zhang X, McCoy MA, Wyss DF, Yang X, Achab A, Soucy K, Montavon DK, Murphy DM, Whitehurst CE. Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors. ACS Med Chem Lett 2011; 2:632-7. [PMID: 24900358 DOI: 10.1021/ml200113y] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2011] [Accepted: 06/24/2011] [Indexed: 12/13/2022] Open
Abstract
A novel series of non-ATP-competitive MK2 inhibitors based on a furan-2-carboxyamide scaffold was discovered through high-throughput screening using the affinity selection-mass spectrometry-based Automated Ligand Identification System platform. Medicinal chemistry efforts optimized the initial screening hit to leadlike compounds with significant improvements in biochemical and cellular potencies, while maintaining excellent kinase selectivity and in vitro pharmacokinetic properties. Biophysical and biochemical studies confirmed the unique non-ATP-competitive binding mode of this series and suggested that highly selective inhibitors of MK2 should be feasible by targeting the outside ATP pocket.
Collapse
Affiliation(s)
- Xiaohua Huang
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Gerald W. Shipps
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Cliff C. Cheng
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Peter Spacciapoli
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Xingmin Zhang
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Mark A. McCoy
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Daniel F. Wyss
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Xianshu Yang
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Abdelghani Achab
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Kyle Soucy
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Donna K. Montavon
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Denise M. Murphy
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| | - Charles E. Whitehurst
- Merck Research Laboratories, 320 Bent Street, Cambridge, Massachusetts 02141, United States
| |
Collapse
|
5
|
Toleikis Z, Cimmperman P, Petrauskas V, Matulis D. Determination of the volume changes induced by ligand binding to heat shock protein 90 using high-pressure denaturation. Anal Biochem 2011; 413:171-8. [DOI: 10.1016/j.ab.2011.02.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2011] [Revised: 02/11/2011] [Accepted: 02/12/2011] [Indexed: 11/26/2022]
|
6
|
Abstract
Measuring the strength of binding of low molecular weight ligands to a target protein is a significant challenge to fragment-based drug discovery that must be solved. Thermal shift assays are uniquely suited for this purpose, due to the thermodynamic effects of a ligand on protein thermal stability. We show here how to implement a thermal shift assay, describing the basic features and analysis of the protein unfolding data. We then describe in detail the effects of a ligand on the observed stability of the protein to produce a shift in stability. The anatomy of ligand-induced thermal shift data is discussed in detail. We describe the unique aspects of concentration-response curves, the effect of protein unfolding energetics, and the stoichiometry of the interaction. We outline a typical assay development strategy for optimizing dye type and concentration, protein concentration, and buffer conditions. Guidelines are presented to demonstrate the limits of detection for weak-binding ligands, as applied to sulfonamide-based inhibitors of carbonic anhydrase II and applied to nucleotide binding to the death-associated protein kinase 1 catalytic domain.
Collapse
Affiliation(s)
- James K Kranz
- Biopharmaceutical Technologies, GlaxoSmithKline Biopharmaceutical Research and Development, Upper Merion, Pennsylvania, USA
| | | |
Collapse
|
7
|
Sorrell FJ, Greenwood GK, Birchall K, Chen B. Development of a differential scanning fluorimetry based high throughput screening assay for the discovery of affinity binders against an anthrax protein. J Pharm Biomed Anal 2010; 52:802-8. [PMID: 20376913 DOI: 10.1016/j.jpba.2010.02.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The anthrax protein protective antigen (PA) is responsible for cell-surface recognition and aids the delivery of the toxic anthrax enzymes into host cells. By targeting PA and preventing it from binding to host cells, it is hoped that the delivery of toxins into the cell will be inhibited. The current assay reported for PA is a low throughput functional assay. Here, the high throughput screening method using differential scanning fluorimetry (DSF) was developed and optimized to screen a number of libraries from various sources including a selection of FDA-approved drugs as well as hits selected by a virtual screening campaign. DSF is a rapid technique that uses fluorescence to monitor the thermal unfolding of proteins using a standard QPCR instrument. A positive shift in the calculated melting temperature (Tm), of the protein in the presence of a compound, relative to the Tm of the unbound protein, indicates that stabilization of the protein by ligand binding may have occurred. Optimization of the melting assay showed SYPRO Orange to be an ideal dye as a marker and lead to the reduction of DMSO concentration to <1% (v/v) in the final assay. The final assay volume was minimized to 25 L with 5 g protein per well of 96-well plate. In addition, a buffer, salt and additive screen lead to the selection of 10 mM HEPES-NaOH pH 7.5, 100 mM NaCl as the assay buffer. This method has been shown here to be useful as a primary method for the detection of small-molecule PA ligands, giving a hit rate of approximately 7%. These ligands can then be studied further using PA functional assays to confirm their biological activities before being selected as lead compounds for the treatment of anthrax.
Collapse
Affiliation(s)
- Fiona J Sorrell
- Department of Chemistry, University of Sheffield, Sheffield S3 7HF, UK
| | | | | | | |
Collapse
|
8
|
Miglani R, Cliffe IA, Voleti SR. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies. Eur J Med Chem 2009; 45:98-105. [PMID: 19850376 DOI: 10.1016/j.ejmech.2009.09.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2008] [Revised: 07/25/2009] [Accepted: 09/17/2009] [Indexed: 11/28/2022]
Abstract
The Ser/Thr protein kinase MAPKAP kinase2 (MAPKAPK2 or MK2) plays an important role in inflammation. A comparison of several crystal structures of MK2 shows that differences in active and inactive conformations result in large part from structural variations within the conformations of the glycine rich loop (p-loop) regions. We propose the most preferred binding conformation of two classes of MK2 inhibitors and suggest plausible critical interactions with active site residues. The predicted binding conformations of the two classes of MK2 inhibitors depend upon their orientation in the active site and activities were well correlated with the sum of D and G scores. A qualitative relationship between the sum of D and G scores and the measured activities can be demonstrated.
Collapse
Affiliation(s)
- Rajni Miglani
- Division of Molecular Modeling, New Drug Discovery Research, Ranbaxy Laboratories Limited, Sector-18, Gurgaon-122001, India.
| | | | | |
Collapse
|
9
|
Forneris F, Orru R, Bonivento D, Chiarelli LR, Mattevi A. ThermoFAD, a Thermofluor-adapted flavin ad hoc detection system for protein folding and ligand binding. FEBS J 2009; 276:2833-40. [PMID: 19459938 DOI: 10.1111/j.1742-4658.2009.07006.x] [Citation(s) in RCA: 154] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In living organisms, genes encoding proteins that contain flavins as a prosthetic group constitute approximately 2-3% of the total. The fluorescence of flavin cofactors in these proteins is a property that is widely employed for biochemical characterisation. Here, we present a modified Thermofluor approach called ThermoFAD (Thermofluor-adapted flavin ad hoc detection system), which simplifies identification of optimal purification and storage conditions as well as high-affinity ligands. In this technique, the flavin cofactor is used as an intrinsic probe to monitor protein folding and stability, taking advantage of the different fluorescent properties of flavin-containing proteins between the folded and denatured state. The main advantage of the method is that it allows a large amount of biochemical data to be obtained using very small amounts of protein sample and standard laboratory equipment. We have explored several cases that demonstrate the reliability and versatility of this technique when applied to globular flavoenzymes, membrane-anchored flavoproteins, and macromolecular complexes. The information gathered from ThermoFAD analysis can be very valuable for any biochemical and biophysical analysis, including crystallisation. The method is likely to be applicable to other classes of proteins that possess endogenous fluorescent cofactors and prosthetic groups.
Collapse
Affiliation(s)
- Federico Forneris
- Department of Genetics and Microbiology, University of Pavia, Italy.
| | | | | | | | | |
Collapse
|
10
|
Cimmperman P, Baranauskiene L, Jachimoviciūte S, Jachno J, Torresan J, Michailoviene V, Matuliene J, Sereikaite J, Bumelis V, Matulis D. A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys J 2008; 95:3222-31. [PMID: 18599640 PMCID: PMC2547457 DOI: 10.1529/biophysj.108.134973] [Citation(s) in RCA: 252] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 06/13/2008] [Indexed: 01/17/2023] Open
Abstract
Equilibrium binding ligands usually increase protein thermal stability by an amount proportional to the concentration and affinity of the ligand. High-throughput screening for the discovery of drug-like compounds uses an assay based on thermal stabilization. The mathematical description of this stabilization is well developed, and the method is widely applicable to the characterization of ligand-protein binding equilibrium. However, numerous cases have been experimentally observed where equilibrium binding ligands destabilize proteins, i.e., diminish protein melting temperature by an amount proportional to the concentration and affinity of the ligand. Here, we present a thermodynamic model that describes ligand binding to the native and unfolded (denatured) protein states explaining the combined stabilization and destabilization effects. The model also explains nonsaturation and saturation effects on the protein melting temperature when the ligand concentration significantly exceeds the protein concentration. Several examples of the applicability of the model are presented, including specific sulfonamide binding to recombinant hCAII, peptide and ANS binding to the Polo-box domain of Plk1, and zinc ion binding to the recombinant porcine growth hormone. The same ligands may stabilize and destabilize different proteins, and the same proteins may be stabilized and destabilized by different ligands.
Collapse
Affiliation(s)
- Piotras Cimmperman
- Laboratory of Biothermodynamics and Drug Design, Institute of Biotechnology, LT-02241 Vilnius, Lithuania
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 2007; 104:20523-8. [PMID: 18077363 DOI: 10.1073/pnas.0708800104] [Citation(s) in RCA: 275] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Protein kinases play a pivotal role in cell signaling, and dysregulation of many kinases has been linked to disease development. A large number of kinase inhibitors are therefore currently under investigation in clinical trials, and so far seven inhibitors have been approved as anti-cancer drugs. In addition, kinase inhibitors are widely used as specific probes to study cell signaling, but systematic studies describing selectivity of these reagents across a panel of diverse kinases are largely lacking. Here we evaluated the specificity of 156 validated kinase inhibitors, including inhibitors used in clinical trials, against 60 human Ser/Thr kinases using a thermal stability shift assay. Our analysis revealed many unexpected cross-reactivities for inhibitors thought to be specific for certain targets. We also found that certain combinations of active-site residues in the ATP-binding site correlated with the detected ligand promiscuity and that some kinases are highly sensitive to inhibition using diverse chemotypes, suggesting them as preferred intervention points. Our results uncovered also inhibitor cross-reactivities that may lead to alternate clinical applications. For example, LY333'531, a PKCbeta inhibitor currently in phase III clinical trials, efficiently inhibited PIM1 kinase in our screen, a suggested target for treatment of leukemia. We determined the binding mode of this inhibitor by x-ray crystallography and in addition showed that LY333'531 induced cell death and significantly suppressed growth of leukemic cells from acute myeloid leukemia patients.
Collapse
|
13
|
Holdgate GA. Thermodynamics of binding interactions in the rational drug design process. Expert Opin Drug Discov 2007; 2:1103-14. [DOI: 10.1517/17460441.2.8.1103] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Geoff A Holdgate
- Global Compound Sciences, Lead Generation - Discovery Enabling Capabilities & Sciences, AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
| |
Collapse
|
14
|
Malawski GA, Hillig RC, Monteclaro F, Eberspaecher U, Schmitz AAP, Crusius K, Huber M, Egner U, Donner P, Müller-Tiemann B. Identifying protein construct variants with increased crystallization propensity--a case study. Protein Sci 2007; 15:2718-28. [PMID: 17132859 PMCID: PMC2242438 DOI: 10.1110/ps.062491906] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
This study describes an efficient multiparallel automated workflow of cloning, expression, purification, and crystallization of a large set of construct variants for isolated protein domains aimed at structure determination by X-ray crystallography. This methodology is applied to MAPKAP kinase 2, a key enzyme in the inflammation pathway and thus an attractive drug target. The study reveals a distinct subset of truncation variants with improved crystallization properties. These constructs distinguish themselves by increased solubility and stability during a parallel automated multistep purification process including removal of the recombinant tag. High-throughput protein melting point analysis characterizes this subset of constructs as particularly thermostable. Both parallel purification screening and melting point determination clearly identify residue 364 as the optimal C terminus for the kinase domain. Moreover, all three constructs that ultimately crystallized feature this C terminus. At the N terminus, only three amino acids differentiate a noncrystallizing from a crystallizing construct. This study addresses the very common issues associated with difficult to crystallize proteins, those of solubility and stability, and the crucial importance of particular residues in the formation of crystal contacts. A methodology is suggested that includes biophysical measurements to efficiently identify and produce construct variants of isolated protein domains which exhibit higher crystallization propensity.
Collapse
|